XML 43 R22.htm IDEA: XBRL DOCUMENT v3.22.2.2
Product Sales (Tables)
 9 Months Ended
Sep. 30, 2022
Revenue from Contract with Customer [Abstract]  
Schedule of product sales
Net product sales consist of the following:
Three Months Ended
September 30,		Nine Months Ended
September 30,
(In millions)2022202120222021
EYLEA®
U.S.$1,629.4 $1,473.4 $4,768.2 $4,245.1 
Libtayo®(a)
U.S.94.7 78.4 264.5 225.5 
ROW(b)
31.0 — 31.0 — 
Praluent®
U.S.29.7 44.8 94.5 130.0 
REGEN-COV®(c)
U.S.— 676.7 — 3,530.1 
Evkeeza®
U.S.13.6 6.6 33.2 9.1 
Inmazeb®
U.S.3.0 — 3.0 — 
ARCALYST®(d)
U.S.— — — 2.2 
$1,801.4 $2,279.9 $5,194.4 $8,142.0 
(a) Prior to July 1, 2022, Regeneron recorded net product sales of Libtayo in the United States and Sanofi recorded net product sales of Libtayo outside the United States. Effective July 1, 2022, the Company began recording net product sales of Libtayo outside the United States. See Note 3 for further details.
(b) Rest of world ("ROW")
(c) Net product sales of REGEN-COV in the United States relate to product sold in connection with our agreements with the U.S. government. See Note 3 for further details.
(d) Effective April 1, 2021, Kiniksa records net product sales of ARCALYST in the United States. Previously, the Company recorded net product sales of ARCALYST in the United States.
Amounts recognized in our Statements of Operations in connection with our collaborations with Sanofi are detailed below:
Statement of Operations ClassificationThree Months Ended
September 30,		Nine Months Ended
September 30,
(In millions)2022202120222021
Antibody:
Regeneron's share of profits in connection with commercialization of antibodiesCollaboration revenue$551.1 *$387.0 $1,463.0 *$975.2 
Sales-based milestone earnedCollaboration revenue$— $50.0 $50.0 $50.0 
Reimbursement for manufacturing of commercial suppliesCollaboration revenue$160.5 $144.7 $466.8 $361.2 
OtherCollaboration revenue$(0.2)$— $28.7 $— 
(Regeneron's obligation for its share of Sanofi R&D expenses)/reimbursements of R&D expenses, net (R&D expense)/reduction of R&D expense$(4.3)$34.9 $59.6 $89.5 
Reimbursement of commercialization-related expenses Reduction of SG&A expense$108.6 $79.0 $311.1 $216.9 
Immuno-oncology:
Regeneron's share of profits (losses) in connection with commercialization of Libtayo outside the United StatesCollaboration revenue$— $(3.0)$6.7 $(12.6)
Reimbursement for manufacturing of ex-U.S. commercial suppliesCollaboration revenue$— $3.1 $4.6 $10.5 
Reimbursement of R&D expensesReduction of R&D expense$— $21.8 $42.7 $66.2 
Reimbursement of commercialization-related expensesReduction of SG&A expense$— $22.8 $41.4 $62.0 
Regeneron's obligation for its share of Sanofi commercial expensesSG&A expense$— $(9.4)$(19.9)$(28.0)
Regeneron's obligation for Sanofi's share of Libtayo U.S. gross profitsCost of goods sold$— $(34.6)$(70.1)$(99.4)
Amounts recognized in connection with up-front payments receivedOther operating income$— $(47.7)$35.1 $(4.1)
* Net of one-time payment of $56.9 million to Sanofi in connection with the amendment to the Antibody License and Collaboration Agreement described below
Amounts recognized in our Statements of Operations in connection with our Bayer collaboration are as follows:
Statement of Operations ClassificationThree Months Ended
September 30,		Nine Months Ended
September 30,
(In millions)2022202120222021
Regeneron's share of profits in connection with commercialization of EYLEA outside the United StatesCollaboration revenue$315.3 $351.0 $993.4 $995.3 
Reimbursement for manufacturing of ex-U.S. commercial suppliesCollaboration revenue$17.5 $14.0 $60.3 $41.6 
One-time payment in connection with change in Japan arrangement
Collaboration revenue$— $— $21.9 $— 
Reimbursement of R&D expensesReduction of R&D expense$11.8 

$14.5 $32.7 $35.2 
Regeneron's obligation for its share of Bayer research and development expenses
R&D expense$(4.7)$(8.0)$(22.4)$(31.4)
Amounts recognized in our Statements of Operations in connection with the Roche Collaboration Agreement are as follows:
Statement of Operations ClassificationThree Months Ended
September 30,		Nine Months Ended
September 30,
(In millions)2022202120222021
Global gross profit payment from Roche in connection with sales of RonapreveCollaboration revenue$6.4 $127.1 $230.9 $361.8 
Schedules of sales to customers as percentage of total gross product revenue Sales to each of these customers as a percentage of the Company's total gross product revenue are as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
2022202120222021
Besse Medical, a subsidiary of AmerisourceBergen Corporation
56 %40 %56 %33 %
McKesson Corporation28 %24 %29 %20 %
U.S. government— %25 %— %38 %